Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Cell Culture Market analysis
Part of: Cell Culture Market (Global)

The UK Cell Culture Market was valued at $1656.8 Million in 2026 and projected to reach to $2900.2 Million by 2031, representing a compound annual growth rate of 11.8%. The UK cell culture market is poised for significant growth through 2031, supported by the nation's commitment to life sciences innovation and substantial investments in biopharmaceutical development.

UK Cell Culture Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Cell Culture Market Trends and Insights

  • Valued at $1,656.8 million in 2026, the UK market is projected to expand to $2,900.2 million by 2031, representing a compound annual growth rate of 11.8%.
  • This expansion reflects the UK's strengthening biopharmaceutical infrastructure, increased investment in regenerative medicine, and growing demand for advanced cell-based therapies and vaccine development platforms. Driving the UK cell culture market's growth are accelerating R&D activities in academic institutions and commercial laboratories, coupled with rising adoption of 3D cell culture technologies and automation solutions.
  • The UK's regulatory environment and access to skilled workforce further support market penetration.
  • Between 2026 and 2031, the UK is expected to capture significant share of European cell culture demand, supported by government initiatives in life sciences and strategic partnerships with global biotech firms. The UK cell culture market remains integral to the country's position as a European innovation hub, with sustained investment in cell therapy manufacturing and contract research organizations driving sustained expansion through 2031..

Key Market Statistics

  • CAGR (2026-2031) 11.8% CAGR
  • Market Size, 2026 ~USD 1656.8 Million
  • Forecast, 2031 ~USD 2900.2 Million
  • Country UK

UK Cell Culture Market Overview

Market Valuation Growth :

The UK cell culture market is valued at $1,656.8 million in 2026 and is projected to reach $2,900.2 million by 2031, demonstrating robust expansion driven by advancing biopharmaceutical capabilities and research investments.

Strong CAGR Performance :

The UK market exhibits an 11.8% CAGR from 2026 to 2031, slightly outpacing the global average of 12.1%, indicating accelerated adoption and innovation within the UK's life sciences sector.

Regenerative Medicine Leadership :

The UK is establishing itself as a hub for regenerative medicine and advanced therapeutics, with increased government and private sector funding supporting cell culture infrastructure and research capabilities.

Biopharmaceutical Infrastructure Expansion :

Strengthening biopharmaceutical infrastructure across the UK, including manufacturing facilities and research institutions, is driving demand for advanced cell culture technologies and solutions.

UK Cell Culture Market Dynamics

  • The market's 11.8% CAGR reflects increasing adoption of cell culture technologies across academic institutions, contract research organizations, and pharmaceutical manufacturers.
  • Key drivers include the expansion of regenerative medicine initiatives, growing demand for personalized medicine, and the UK's strategic positioning as a European life sciences leader.
  • Government support through funding programs and regulatory frameworks continues to facilitate market expansion and attract international investment in cell culture capabilities..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The UK cell culture market will grow from $1,656.8M (2026) to $2,900.2M (2031) at an 11.8% CAGR.
    • The UK's advanced regulatory framework and skilled workforce position it as a European leader in cell culture innovation.
    • Rising demand for regenerative medicine and cell-based therapies is accelerating UK market expansion.
    • The UK's investment in biopharmaceutical infrastructure and contract research organizations supports sustained growth through 2031.

    Cell Culture Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment TISSUE ENGINEERING & REGENERATIVE MEDICINE (Application)
    Forecast Period 2026–2031
    Growth Rate CAGR of 12.1% from 2026 to 2031
    Largest Segment PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 33 (2026)
    Revenue Forecast (Billions) ~USD 58.42 (2031)
    Segments Covered Product, Type, Application, End User

    UK Cell Culture Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Consumables
    • Equipment

    By Type

    • Adult Bovine Sera
    • Antibiotics/Antimycotics
    • Attachment & Matrix Factors
    • Autoclaves
    • Balanced Salt Solutions
    • Bhk Media
    • Bioreactors
    • Biosafety Cabinets
    • Buffers & Chemicals
    • Carbon Dioxide Incubators
    • Cell & Gene Therapy
    • Cell Counters
    • Cell Dissociation Reagents
    • Cell Factory Systems/Cell Stacks
    • Centrifuges
    • Chemically-Defined Media
    • Cho Media
    • Classical Media & Salts
    • Contamination Detection Kits
    • Cryoprotective Reagents
    • Cryostorage Systems
    • Fetal Bovine Sera
    • Filtration Systems
    • Flasks
    • Growth Factors
    • Hek 293 Media
    • Media
    • Microscopes
    • Monoclonal Antibody Production
    • Multiwell Plates
    • Other Animal Sera
    • Other Consumables & Accessories
    • Other Media
    • Other Reagents
    • Other Serum-Free Media
    • Other Supporting Equipment
    • Other Therapeutic Protein Production
    • Other Tissue Engineering & Regenerative Medicine Applications
    • Petri Dishes
    • Reagents
    • Refrigerators & Freezers
    • Roller/Roux Bottles
    • Sera
    • Sera, Media, And Reagents
    • Serum-Free Media
    • Serum-Free Stem Cell Media
    • Specialty Media
    • Stem Cell Culture Media
    • Storage Equipment
    • Supplements
    • Supporting Equipment
    • Vaccine Production
    • Vero Cell Media
    • Vessels

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Screening & Development
    • Other Applications
    • Tissue Engineering & Regenerative Medicine

    By End User

    • Academic & Research Institutes
    • Hospitals & Diagnostic Laboratories
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    UK: CELL CULTURE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES197.7209.1223.3240.1260.3284.7313.4347.49.2
    HOSPITALS & DIAGNOSTIC LABORATORIES261.4279.4301.8328.2360.1398.6444.5499.210.6
    OTHER END USERS131.4141.6154.1168.9186.8208.4234.3265.411.5
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES813.7887.4977.71084.71214.41371.51560.51788.212.8
    TOTAL1404.21517.41656.81821.82021.62263.22552.82900.211.8

    Target Audience

    • UK Biopharmaceutical Manufacturers : Manufacturers need UK-specific market data to optimize production strategies, assess capacity expansion requirements, and identify growth opportunities within the domestic cell culture supply chain.
    • Contract Research Organizations (CROs) : UK-based CROs require detailed market insights to benchmark service offerings, identify client demand trends, and plan investments in cell culture capabilities and infrastructure.
    • Academic & Research Institutions : UK universities and research centers need market intelligence to secure funding, justify equipment investments, and align research initiatives with commercial opportunities in cell culture technology.
    • Cell Culture Technology Suppliers : Equipment and reagent suppliers targeting the UK market require localized data to develop go-to-market strategies, identify key customer segments, and forecast demand for their products.
    • Healthcare Investment & Venture Capital Firms : UK-focused investors need comprehensive market analysis to evaluate investment opportunities in cell culture startups, identify growth potential, and assess competitive positioning within the British life sciences sector.

    Key Companies in the UK Cell Culture Market

    CompanyHQOwnershipStrongest segments
    PATHEON INCNetherlandsPrivate CompanyDrug product services (oral, sterile, packaging, lifecycle management),Pharmaceutical development services (formulation, analytical, clinical supply),Drug substance services (small-molecule and biologics APIs),
    BIOMERIEUX S.A.FrancePublic CompanyClinical microbiology (culture media, VITEK, blood culture, ID/AST),Molecular and syndromic diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and CLIA (VIDAS, Hybiome),
    SIGMA-ALDRICH CORPORATIONUnited StatesPrivate CompanyChemicals, biochemicals, and analytical reagents,Cell culture media, critical raw materials, and bioprocess solutions,Filtration, water purification, and labware,
    HI-MEDIAFrancePublic CompanyIn-content native and integrated formats,Geo-marketing and location-based solutions,Managed campaign and data-driven services,
    REPLIGEN CORPORATIONUnited StatesPublic CompanyFiltration and cell retention (XCell ATF, KrosFlo, TangenX, ProConnex TFDF),Chromatography (OPUS columns, KRM systems, resins, ELISA kits),Process analytics and PAT (PATsmart suite, SoloVPE/FlowVPE, ZipChip, REBEL),
    QIAGEN NVNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease assays,Oncology and sexual & reproductive health assays,
    QUIDEL CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care,
    FLUOR CORPORATIONUnited StatesPublic CompanyEnergy Solutions,Urban Solutions,Mission Solutions,
    TECHNICOLOR SAFrancePublic CompanyBroadband gateways and routers (fiber, xDSL, cable),Wi-Fi extenders, Wi-Fi XL, homeware and in-home networking,Video set-top boxes, dongles, smart media devices,
    EIKEN CHEMICAL CO., LTD.JapanPublic CompanyFecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents (clinical),Urinalysis test strips and analyzers,
    MAXCYTE, INCUnited StatesPublic CompanyExPERT Instruments (ATx, STx, GTx, VLx),Consumables (Processing Assemblies, Buffers, Accessories),Licensing and Technology Access,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences tools and genomic medicine,Diagnostics,
    MERCK KGAAGermanyPublic CompanyLife Science (tools, consumables, bioprocessing, CDMO),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, equipment),
    SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, cell culture, fluid and process chromatography/filtration),Lab products and services (filtration, water systems, weighing, pipettes, microbiological testing),Analytical and PAT solutions (BLI, cytometry screening, live-cell imaging, SPR, data analytics),
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, hardware, connectors),Display glass substrates (LCD/OLED),Specialty materials and optics,
    FUJIFILM HOLDINGS CORPORATIONJapanPublic CompanyHealthcare (medical systems, CDMO, pharma, regenerative medicine, cosmetics/supplements),Electronics (display/touch panels, semiconductor and display materials, storage media, industrial equipment, fine chemicals),Business Innovation (office equipment, document solutions, graphic communications, industrial inkjet),
    BDUnited StatesPublic CompanyMedical Essentials (syringes, needles, vascular access, sharps, enteral),Connected Care (infusion pumps, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, related solutions),
    EPPENDORF SEGermanyPrivate CompanyLiquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),
    LONZASwitzerlandPublic CompanyIntegrated Biologics (mammalian DS/DP platforms),Advanced Synthesis (small molecules, HPAPIs, ADCs/bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
    GETINGESwedenPublic CompanyAcute Care Therapies (ECMO, ventilation, monitoring, ICU infrastructure, drainage),Surgical Workflows (OR equipment, anesthesia, OR integration, sterile supply management),Life Science (sterilization, biocontainment, bioprocess, labware cleaning, vivarium),
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab (Services, Consumables, Software),Applied Markets (GC, MS, Spectroscopy, Vacuum, Remarketed),
    BIO-TECHNEUnited StatesPublic CompanyProtein Sciences (reagents and proteomic tools),Diagnostics products and controls,Genomics and spatial biology,

    PATHEON INC

    Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology services sector.

    BIOMERIEUX S.A.

    bioMérieux S.A. is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics and microbiology testing solutions.

    SIGMA-ALDRICH CORPORATION

    Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees, supplying research chemicals and biochemicals globally.

    HI-MEDIA

    HI-MEDIA is a French public company founded in 1996 with 29 employees that manufactures culture media and laboratory reagents for microbiology.

    REPLIGEN CORPORATION

    Repligen Corporation is a United States-based public company founded in 1981 with 2,000 employees providing bioprocessing solutions and chromatography products.

    QIAGEN NV

    QIAGEN NV is a Netherlands-based public company founded in 1984 with 5,500 employees specializing in molecular diagnostics and sample preparation technologies.

    QUIDEL CORPORATION

    Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees developing rapid diagnostic testing solutions.

    FLUOR CORPORATION

    Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees providing engineering, procurement, and construction services.

    TECHNICOLOR SA

    Technicolor SA is a France-based public company founded in 1985 with 1,552 employees offering media and entertainment technology services.

    EIKEN CHEMICAL CO., LTD.

    Eiken Chemical Co., Ltd. is a Japan-based public company founded in 1939 with 696 employees manufacturing diagnostic reagents and laboratory chemicals.

    MAXCYTE, INC

    MaxCyte, Inc. is a United States-based public company founded in 1998 with 91 employees developing cell engineering and electroporation technologies.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical instruments globally.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating diversified businesses in life sciences, diagnostics, and environmental solutions.

    MERCK KGAA

    Merck KGaA is a Germany-based public company founded in 1668 with 59,077 employees providing pharmaceuticals, chemicals, and life science products and services.

    SARTORIUS AG

    Sartorius AG is a Germany-based public company founded in 1870 with 14,242 employees manufacturing laboratory and bioprocess equipment for the life sciences industry.

    CORNING INCORPORATED

    Corning Incorporated is a United States-based public company founded in 1851 with 67,200 employees producing specialty glass, ceramics, and optical products.

    FUJIFILM HOLDINGS CORPORATION

    Fujifilm Holdings Corporation is a Japan-based public company founded in 1934 with 73,526 employees operating in imaging, information, and document solutions.

    BD

    BD is a United States-based public company founded in 1897 with 72,000 employees manufacturing medical devices, diagnostics, and life science tools.

    EPPENDORF SE

    Eppendorf SE is a Germany-based private company founded in 1945 with 4,358 employees manufacturing laboratory equipment and consumables for life sciences research.

    LONZA

    Lonza is a Switzerland-based public company founded in 1897 with 20,000 employees providing pharmaceutical and biotechnology manufacturing services and products.

    GETINGE

    Getinge is a Sweden-based public company founded in 1904 with 11,754 employees manufacturing medical devices and systems for healthcare and life sciences.

    AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.

    BIO-TECHNE

    Bio-Techne is a United States-based public company founded in 1976 with 3,100 employees providing protein reagents, antibodies, and analytical instruments for life sciences research.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Access precise valuation data for the UK cell culture market with detailed forecasts from 2026-2031, enabling accurate budget allocation and investment planning tailored to the British market landscape.
    • Competitive Intelligence : Understand the UK's market dynamics relative to global trends, identifying competitive advantages and market positioning opportunities specific to British biopharmaceutical and research organizations.
    • Growth Driver Analysis : Gain insights into UK-specific factors driving the 11.8% CAGR, including regenerative medicine investments, regulatory environment, and infrastructure development unique to the British life sciences sector.
    • Strategic Investment Guidance : Make informed decisions on facility expansion, technology adoption, and partnership development within the UK market with comprehensive data on emerging opportunities and market segments.
    • Regulatory & Policy Context : Understand the UK regulatory framework and government initiatives supporting cell culture innovation, essential for navigating market entry and expansion strategies in the British life sciences ecosystem.

    Frequently asked questions

    What is the projected size of the UK cell culture market by 2031?

    The UK cell culture market is forecast to reach $2,900.2 million by 2031, up from $1,656.8 million in 2026.

    What is the CAGR for the UK cell culture market?

    The UK cell culture market is expected to grow at a compound annual growth rate of 11.8% between 2026 and 2031.

    What factors are driving growth in the UK cell culture market?

    Key drivers include increased R&D investment in biopharmaceuticals, adoption of advanced 3D cell culture technologies, growing regenerative medicine demand, and the UK's supportive regulatory environment.

    How does the UK cell culture market compare to Europe?

    The UK represents a significant portion of the European cell culture market, leveraging its advanced infrastructure, skilled workforce, and strategic position as a life sciences innovation hub.

    What applications are fueling UK cell culture market demand?

    Primary applications include vaccine development, cell therapy manufacturing, drug discovery, and regenerative medicine research across academic and commercial sectors in the UK.

    RESEARCH METHODOLOGY

    This research study relied extensively on secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cell culture market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell culture market. The secondary sources used for this study include World Health Organization (WHO), Food and Drug Administration, American Society for Cell Biology (ASCB), National Institutes of Health (NIH), International Society for Cell & Gene Therapy (ISCT), American Society for Gene and Cell Therapy (ASGCT), Centers of Disease Control and Prevention (CDC), International Serum Industry Association (ISIA), Pharmaceutical Research and Manufacturers of America (PhRMA), International Society for Vaccines (ISV), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Society for In Vitro Biology (SIVB), Japan Agency for Medical Research and Development, European Federation of Pharmaceutical Industries and Associations (EFPIA), American Type Culture Collection (ATCC), and the Alliance for Regenerative Medicine (ARM); corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess the market's future prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Cell Culture Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell culture market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Cell Culture Market : Top-Down and Bottom-Up Approach

    Cell Culture Market Top Down and Bottom Up Approach

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Cell culture refers to the removal of cells from an animal or plant and their subsequent growth in an artificial environment under controlled conditions. It is a process of growing cells outside their natural environment, typically in a laboratory setting. This technique allows researchers to study cells in a controlled environment, providing insights into their behavior, growth, metabolism, and response to various stimuli.

    The scope of this report includes products such as equipment and consumables, such as media, sera, reagents, vessels, bioreactors, storage equipment, and other cell culture-supporting equipment that support the cell culture process.

    Key Stakeholders

    • Cell Culture Equipment and Reagents Manufacturers
    • Analytical and Life Science Instrumentation Companies
    • Academic and Research Institutes
    • Pharmaceutical and Biotechnology Companies
    • Life Science Companies
    • Venture Capitalists and Investors
    • Government Organizations
    • Private Research Firms
    • Contract Research Organizations (CROs)
    • Hospitals and Diagnostic Laboratories
    • Cell Banks

    Report Objectives

    • To define, describe, and forecast the global cell culture market based on product, application, end user, and region
    • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall cell culture market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
    • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the cell culture market
    • To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the cell culture market

    Available customizations:

    Based on the given market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following customization options are available for this report:

    Portfolio Analysis

    • Product Matrix, which gives a detailed comparison of the product portfolios of the top five companies.

    Regional Analysis

    • A further breakdown of the Rest of Europe cell culture market, by country
    • A further breakdown of the Rest of Asia Pacific cell culture market, by country
    • A further breakdown of the Rest of Latin America cell culture market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five).

    Get the Full Cell Culture Market Report

    Full forecast, segment splits, and company analysis for all Cell Culture Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status